Interest in epicardial adipose tissue (EAT) is growing rapidly, and research in this area
appeals to a broad, multidisciplinary audience. EAT is unique in its anatomy and …

Alterations in cardiac energy metabolism contribute to the severity of heart failure. However,
the energy metabolic changes that occur in heart failure are complex and are dependent not …

Peroxisome proliferator-activated receptor-α (PPARα), PPARδ and PPARγ are transcription
factors that regulate gene expression following ligand activation. PPARα increases cellular …

Heart failure with preserved ejection fraction (HFpEF) affects half of all patients with heart
failure worldwide, is increasing in prevalence, confers substantial morbidity and mortality …

The prevalence of heart failure is on the rise and imposes a major health threat, in part, due
to the rapidly increased prevalence of overweight and obesity. To this point …

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …

Abstract Sodium–glucose cotransporter (SGLT) 2 inhibitors have been demonstrated to
reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials …

Mitochondrial dysfunction has been implicated in the development of heart failure. Oxidative
metabolism in mitochondria is the main energy source of the heart, and the inability to …

Previous microbiome and metabolome analyses exploring non-communicable diseases
have paid scant attention to major confounders of study outcomes, such as common, pre …

Despite major progress in interventional and medical treatments, myocardial infarction (MI)
and subsequent development of heart failure (HF) are still associated with high mortality …